WOUND CLOSURE SYSTEMS, DEVICES AND METHODS INCORPORATING THERAPEUTIC DEVICES
20240000455 ยท 2024-01-04
Inventors
- Alison Bick (Raritan, NJ, US)
- Julian Quintero (Flemington, NJ, US)
- Jonathan Syby (Raritan, NJ, US)
- Leo Kriksunov (Ithaca, NY, US)
Cpc classification
A61M1/915
HUMAN NECESSITIES
A61F13/05
HUMAN NECESSITIES
A61F13/00063
HUMAN NECESSITIES
A61M35/00
HUMAN NECESSITIES
International classification
A61B17/08
HUMAN NECESSITIES
A61M1/00
HUMAN NECESSITIES
Abstract
A wound closure system includes a porous mesh, a first pressure sensitive adhesive (PSA) applied to a top surface of the porous mesh, a removable first liner covering the first PSA, a second PSA applied to a bottom surface of the porous mesh, and a removable second liner covering the second PSA. The second PSA is stronger or denser than the first PSA. A method of using the wound closure system includes removing the second liner to expose the second PSA, pressing the second PSA against skin to approximate wound edges, removing the first liner to expose the first PSA, and pressing a therapeutic device against the first PSA to secure the therapeutic device to the porous mesh. A liquid adhesive is applied over the porous mesh and the therapeutic device, and then cured for binding the porous mesh to skin and binding the therapeutic device to the porous mesh.
Claims
1. A wound closure system comprising: a porous mesh having a top surface and a bottom surface; a first pressure sensitive adhesive applied to the top surface of said porous mesh; a removable first liner covering said first pressure sensitive adhesive; a second pressure sensitive adhesive applied to the bottom surface of said porous mesh; a removable second liner covering said second pressure sensitive adhesive; said second pressure sensitive adhesive being stronger or denser than said first pressure sensitive adhesive.
2. The wound closure system as claimed in claim 1, further comprising a cross-linking or polymerization accelerator or catalyst disposed in or on said porous mesh.
3. The wound closure system as claimed in claim 1, wherein said porous mesh is flat, elongated along a longitudinal axis, and has a plurality of openings extending between the top and bottom surfaces thereof.
4. The wound closure system as claimed in claim 1, wherein said removable first liner is configured to be peeled away from the top surface of said porous mesh for exposing said first pressure sensitive adhesive, and wherein said removable second liner is configured to be peeled away from the bottom surface of said porous mesh for exposing said second pressure sensitive adhesive.
5. A method of using said wound closure system as claimed in claim 1, comprising: peeling said removable second liner away from the bottom surface of said porous mesh to expose said second pressure sensitive adhesive applied to the bottom surface of said porous mesh; pressing said second pressure sensitive adhesive applied to the bottom surface of said porous mesh against skin of a patient to approximate opposing edges of a wound; peeling said removable first liner away from the top surface of said porous mesh to expose said first pressure sensitive adhesive applied to the top surface of said porous mesh; pressing a therapeutic device against said first pressure sensitive adhesive to secure said therapeutic device over the top surface of said porous mesh; applying a liquid adhesive over the top surface of said porous mesh and at least a portion of said therapeutic device; allowing said liquid adhesive to cure for binding said porous mesh to the skin and binding said therapeutic device to said porous mesh.
6. The method as claimed in claim 5, wherein the pressing step comprises aligning said therapeutic device with the wound.
7. The method as claimed in claim 6, further comprising using said therapeutic device for draining exudate from the wound or infusing saline or medication into the wound.
8. The method as claimed in claim 5, wherein said liquid adhesive comprises a rapidly polymerizable or cross-linkable liquid adhesive.
9. The method as claimed in claim 5, wherein said therapeutic device is selected from the group of devices consisting of negative pressure wound therapy devices, negative pressure pumps, fluid suction devices, elongated tubes including drainage tubes and infusion tubes, elongated tubes having first and second mesh wings extending along lateral sides thereof, cannulas, and wound monitoring sensors.
10. A kit comprising: a wound closure system including a porous mesh having a top surface and a bottom surface, a first pressure sensitive adhesive applied to the top surface of said porous mesh, a removable first liner covering said first pressure sensitive adhesive, a second pressure sensitive adhesive applied to the bottom surface of said porous mesh, and a removable second liner covering said second pressure sensitive adhesive, said second pressure sensitive adhesive being stronger or denser than said first pressure sensitive adhesive; and a rapidly polymerizable liquid adhesive disposed within a dispenser container.
11. The kit as claimed in claim 10, further comprising one or more therapeutic devices configured to be secured over the top surface of said porous mesh.
12. The kit as claimed in claim 11, wherein said one or more therapeutic devices are selected from the group of devices consisting of negative pressure wound therapy devices, negative pressure pumps, fluid suction devices, elongated tubes including drainage tubes and infusion tubes, elongated tubes having first and second mesh wings extending along lateral sides thereof, cannulas, and wound monitoring sensors.
13. The kit as claimed in claim 10, further comprising a cross-linking or polymerization accelerator or catalyst disposed in or on said porous mesh.
14. A wound closure system comprising: a porous mesh having a top surface and a bottom surface; the bottom surface of said porous mesh being adhered to skin for approximating opposing edges of a wound; a therapeutic device including an elongated tube secured to the top surface of said porous mesh and overlying the wound, said elongated tube being configured for draining exudate from the wound; a liquid adhesive covering the top surface of said porous mesh and at least a portion of said elongated tube.
15. The wound closure system as claimed in claim 14, said therapeutic device further comprising first and second mesh wings secured to said elongated tube and extending along respective lateral sides of said elongated tube, wherein said liquid adhesive covers said first and second mesh wings for securing said therapeutic device to the top surface of said porous mesh.
16. The wound closure system as claimed in claim 14, wherein said elongated tube comprises a first elongated conduit that is coupled with a vacuum or negative pressure pump for draining the exudate from the wound.
17. The wound closure system as claimed in claim 16, wherein said elongated tube comprises a second elongated conduit that is coupled with a positive pressure pump configured to force saline or medication into said elongated tube for infusing the wound with the saline or the medication.
18. The wound closure system as claimed in claim 14, wherein said liquid adhesive is a topical skin adhesive or a rapidly polymerizable adhesive that forms an air-tight seal around the wound.
19. The wound closure system as claimed in claim 18, wherein the air-tight seal formed by said liquid adhesive is waterproof or comprises an antimicrobial barrier.
20. The wound closure system as claimed in claim 14, further comprising a cross-linking or polymerization accelerator or catalyst disposed in or on said porous mesh.
Description
BRIEF DESCRIPTION OF THE DRAWINGS
[0098]
[0099]
[0100]
[0101]
[0102]
[0103]
[0104]
[0105]
[0106]
[0107]
[0108]
[0109]
[0110]
[0111]
[0112]
[0113]
[0114]
[0115]
[0116]
[0117]
[0118]
[0119]
[0120]
[0121]
[0122]
[0123]
[0124]
[0125]
DETAILED DESCRIPTION OF PREFERRED EMBODIMENTS
[0126] Referring to
[0127] The porous mesh 102 may be woven, non-woven, extruded, punched, perforated, molded, etc. In one embodiment, the porous mesh may be similar to a mesh patch sold under the federally registered trademark PRINEO by Ethicon, Inc. of Somerville, New Jersey. In one embodiment, the porous mesh 102 may be coated and/or impregnated with an initiator or accelerator of polymerization.
[0128] The porous mesh 102 may be of any shape that is necessary to cover a wound or incision, such as elliptical, circular, rectangular, square, etc. The porous mesh may have a length to width ratio of about 2:1 to 20:1. In one embodiment, the length of the porous mesh 102 may be about 10-50 cm. In one embodiment, the width of the porous mesh 102 may be about 2-10 cm.
[0129] In one embodiment, the openings 108 of the porous mesh 102 may be of any shape, including round, rectangular, triangular, elliptical, etc. The openings 108 may have diameters of about 0.2-2 mm. In one embodiment, the areas of the individual openings 108 may be from about 0.04 mm.sup.2 to about 4 mm.sup.2.
[0130] In one embodiment, the wound closure system 100 preferably includes a first pressure sensitive adhesive 110 that overlies the top surface 104 of the porous mesh 102. In one embodiment, a removable top liner 112 desirably covers the first pressure sensitive adhesive 110 and the top surface 104 of the porous mesh 102. In one embodiment, the removable top liner may be peeled away from the top surface 104 of the porous mesh 102 for exposing the first pressure sensitive adhesive 110 that overlies the top surface of the porous mesh. The first pressure sensitive adhesive 110 that overlies the top surface 104 of the porous mesh 102 may be utilized for securing a therapeutic device, such as a negative pressure wound therapy (NPWT) device, over the top surface of the porous mesh.
[0131] In one embodiment, the wound closure system 100 preferably includes second pressure sensitive adhesive 114 that overlies the bottom surface 106 of the porous mesh 102. In one embodiment, a removable bottom liner 116 desirably covers the second pressure sensitive adhesive 114 and the bottom surface 106 of the porous mesh 102. The removable bottom liner may be peeled away from the bottom surface 106 of the porous mesh 102 for exposing the second pressure sensitive adhesive 114 that overlies the bottom surface of the porous mesh. The second pressure sensitive adhesive 114 that overlies the bottom surface 106 of the porous mesh 102 may be utilized for securing the porous mesh to skin of a patient for approximating the opposing edges of a wound or incision.
[0132] In one embodiment, the releasable top and bottom liners 112, 116 may be made of synthetic or natural polymers that are easily peelable from the respective first and second pressure sensitive adhesives 110, 114.
[0133] Referring to
[0134] Referring to
[0135] Referring to
[0136] The first pressure sensitive adhesive traces 110A-110M may be in a form of linear segments of pressure sensitive adhesive (as shown in
[0137] Referring to
[0138] The second pressure sensitive adhesive traces 114A-114Y may be in a form of linear segments of pressure sensitive adhesive (as shown in
[0139] Referring to
[0140] In one embodiment, the first and second pressure sensitive adhesives may comprise water soluble pressure sensitive adhesives including hydrocolloids; homo-polymer emulsion (PVA); water-based acrylic adhesives; polyurethane dispersions (PUDs); polyethylene glycol; dextrin/starch-based adhesives; N-vinyl pyrrolidone copolymers; polyvinyl alcohol; cellulose ethers; methylcellulose; carboxymethylcellulose; polyvinylpyrrolidone; polyvinyl acetates, or water insoluble pressure sensitive adhesives including acrylic adhesives; cyanoacrylate adhesives; epoxy; silicone based adhesives; and urethane.
[0141] Referring to
[0142] The porous mesh 102 is used to approximate and hold in apposition or close approximation the edges of the wound, using the second pressure sensitive adhesive traces 114A-114Y (
[0143] In one embodiment, after the porous mesh 102 has been secured to the skin for approximating the skin edges of the wound, the removable top liner 112 (
[0144] In one embodiment, a therapeutic device 126, such as a negative pressure wound therapy (NPWT) device, may be pressed onto the first pressure sensitive adhesive 110 that overlies the top surface 104 of the porous mesh 102 for securing the therapeutic device 126 over the top surface 104 of the porous mesh 102. The therapeutic device may be activated for generating negative pressure and/or a vacuum for draining bodily fluids from the wound. In one embodiment, the wound closure system 100 preferably includes a cannula 128 that may be coupled with the therapeutic device 126 for draining fluids (e.g., wound exudate) that are suctioned by the therapeutic device 126.
[0145] Referring to
[0146] In one embodiment, the longitudinal axis of the porous mesh 102 is aligned with and superimposed over the wound. The positioning of porous mesh over the wound is performed so that the longitudinal axis is aligned with the wound and overlaps the ends of the wound (i.e., the longitudinal axis of the porous mesh is in registration the wound or surgical incision).
[0147] Referring to
[0148] The liquid adhesive 130 may be a polymerizable or cross-linkable adhesive that is applied over the porous mesh 102 and the therapeutic device 126. The liquid adhesive 130 may be expressed from a container having a porous tip impregnated with a polymerization or cross-linking accelerator or initiator.
[0149] In one embodiment, the liquid adhesive does not contain a polymerization or cross-linking accelerator or initiator, rather the polymerization or cross-linking accelerator or activator/initiator may be present on or in the porous mesh 102 in a releasable or reactive form (i.e., available for rapid reaction when contacted by the liquid adhesive 130).
[0150] In one embodiment, after being applied over the porous mesh 102 and the therapeutic device 126, the liquid adhesive 130 preferably polymerizes and/or cross-links and solidifies, establishing a secure bond with the skin, the porous mesh 102, and the therapeutic device 126.
[0151] In one embodiment, the liquid adhesive 130 is polymerized or is crosslinked polymerized or is cross-linked after coming in contact with initiators and/or accelerators of adhesive polymerization and/or cross-linking, including naturally found initiators on the tissue, such as moisture, traces of proteins, etc. Such initiators and/or accelerators may be coated or disposed non-releasably, i.e., immobilized in or on the porous mesh 102 while retaining activity to initiate or accelerate polymerization and/or cross-linking. In one embodiment, initiators and/or accelerators are disposed releasably, i.e., they can be at least partially released into and mix with the liquid adhesive 130.
[0152] In one embodiment, the liquid adhesive 130 is polymerized or is cross-linked after coming in contact with initiators and/or accelerators releasably disposed in or on the porous mesh 102. Rapid polymerization and/or crosslinking of the liquid adhesive 130 results in bonding the porous mesh 102 to tissue (e.g., skin).
[0153] The liquid adhesive 130 may be any type of biocompatible and rapidly cross-linkable and/or polymerizable compound or mixture of compounds. As used herein, the terms rapidly cross-linkable and/or polymerizable mean that after initiators or accelerators are added, or after the adhesive is formed from two or more components, it is capable of curing, i.e., cross-linking and/or polymerizing within 0.2 minutes to about 20 minutes, and more preferably within 0.5-10 minutes. In one embodiment, the liquid adhesive may cure in about one minute.
[0154] In one embodiment, the liquid adhesive 130 may be formed prior to application onto the porous mesh 102, for instance by mixing two components contained in separate barrels or a two-barrel syringe, and passing the two components through a mixing tip. In this embodiment, there may be no crosslinking initiator or accelerator disposed inside of porous mesh 20. In one embodiment, the liquid adhesive 130 may be formed by mixing fibrinogen and thrombin together.
[0155] In one embodiment, the liquid adhesive 130 may comprise fibrinogen, and a crosslinking initiator or accelerator that is disposed inside the porous mesh 102 comprises thrombin.
[0156] Many other adhesive formulations may be used and are known to a skilled artisan. For example, mixtures containing PEG succinimidyl glutarate may be used as a liquid adhesive.
[0157] In certain embodiments, initiators and/or accelerators or rate modifiers of adhesive polymerization or cross-linking may be releasably disposed on the porous mesh 102 or releasably incorporated into the porous mesh. For example, one or more chemical substances may be dispersed in or on the porous mesh such as being chemically bound, physically bound, coated, absorbed, or adsorbed to the porous mesh.
[0158] For example, a polymerization initiator or accelerator or rate modifier may be loaded in or on the porous mesh so that the initiator or rate modifier provides the desired initiation or rate modification effect to a subsequently applied polymerizable adhesive composition. The polymerization initiator or rate modifier may be immobilized in or on porous mesh so that the initiator or rate modifier does not become detached from the porous mesh and its residues are dispersed in the resultant polymeric material. Alternatively, for example, the polymerization initiator or rate modifier may be initially attached to the porous mesh, but only in such a manner that it becomes mobilized or solubilized by a subsequently applied polymerizable adhesive composition and dispersed in the resultant polymeric material.
[0159] If desired, a combination of chemical substances may also be provided in or on porous mesh, to provide multiple effects. For example, a first chemical species (such as a polymerization initiator or rate modifier) may be immobilized in or on the mesh, while a second, different chemical species (such as a bioactive material) may be detachably attached to the mesh.
[0160] When present in or on the porous mesh, the chemical substances (i.e., polymerization initiator, rate modifier, and/or bioactive materials, or other additives), may be incorporated in or on the porous mesh in any suitable manner. For example, the chemical substance may be added to the porous mesh by contacting the mesh with a solution, mixture, or the like including the chemical substances. The chemical substance may be added to the mesh, for example, by dipping, spraying, roll coating, gravure coating, brushing, vapor deposition, or the like. Alternatively, the chemical substance may be incorporated into or onto the porous mesh during manufacture of the mesh, such as during molding.
[0161] The polymerization initiator or rate modifier loaded in or on the porous mesh may provide a number of advantages (e.g., to provide shorter polymerization time). The concentration of the polymerization initiator or rate modifier may be increased to provide even shorter (i.e., faster) polymerization time. Because the polymerization initiator or rate modifier is loaded directly in or on the porous mesh, it is not necessary to mix the polymerizable adhesive composition with a polymerization initiator or rate modifier prior to application. This may allow a longer working time, where the polymerizable monomer composition may be more precisely and carefully applied over a longer period of time. Such suitable initiators are known in the art and are described, for example, in U.S. Pat. Nos. 5,928,611 and 6,620,846 and U.S. Patent Application Publication No. 2002/0037310, the disclosures of which are hereby incorporated by reference herein.
[0162] In one embodiment, the therapeutic device 126 is a negative pressure wound therapy (NPWT) device that is configured for generating negative pressure for draining exudate from the wound. The wound exudate drawn into the negative pressure wound therapy device 126 may be directed into the cannula 128 for draining the wound exudate away from the patient.
[0163] Use of Wound Closure Systems. In one embodiment, application of a wound closure system may be performed in one or more of the steps disclosed below.
[0164] In one embodiment, standard surgical practices are utilized for preparing the wound including thorough wound cleansing before application of the porous mesh 102 (
[0165] In one embodiment, a sterile gauze may be used to dry the wound, such as patting the wound with the sterile gauze. Drying the wound will ensure direct tissue contact for adherence of the second pressure sensitive adhesive 114 and the porous mesh 102 (
[0166] In one embodiment, the wound closure system including the porous mesh, the therapeutic device, and the liquid adhesive are preferably aseptically transferred into a sterile field.
[0167] Referring to
[0168] In one embodiment, a surgeon will hold the mesh 102 by the corners of the peripheral sections 124A, 1248 of the bottom liner 116 (
[0169] In one embodiment, the porous mesh is positioned so that of the mesh is on either side of the wound or incision, ensuring approximately 1 cm of the mesh extends beyond the ends of the wound or incision. In one embodiment, a surgeon gently presses on the porous mesh to ensure intimate contact of the bottom surface of the porous mesh to a selected side of the wound. In one embodiment, the porous mesh may be gently pulled perpendicularly over the wound while adjusting the porous mesh with fingers or forceps to achieve skin edge approximation and affix the remainder of the porous mesh to the other side of the wound. If there are areas where the porous mesh is loose, a surgeon may gently pass a gloved finger or instrument over the affected area of the porous mesh to ensure complete adherence of the mesh to the skin.
[0170] In one embodiment, after the skin edges have been approximated and the porous mesh is deemed to be properly affixed to the skin, the first and second peripheral sections 124A, 1248 of the removable bottom liner 116 may be peeled away from the bottom surface of the porous mesh for adhering peripheral sections of the porous mesh to the skin.
[0171] In one embodiment, a sterile cutting tool may be utilized to trim the ends of the porous mesh, if necessary, to ensure that about one (1) cm of porous mesh material extends beyond the ends of the wound or incision.
[0172] In one embodiment, the first and second peripheral sections of the removable top liner 112 (
[0173] In one embodiment, the therapeutic device 126 may be pressed against the first pressure sensitive adhesive 110 applied to the top surface 104 of the porous mesh 102 to secure the therapeutic device in place atop the porous mesh.
[0174] In one embodiment, after medical personnel ensure that the porous mesh is in intimate contact with the skin and after the therapeutic device is secured atop the porous mesh, the liquid adhesive may be applied.
[0175] In one embodiment, immediately after the therapeutic device has been placed atop the porous mesh, the liquid adhesive 130 is preferably applied over the porous mesh and at least a portion of the therapeutic device 126. In one embodiment, immediately prior to applying and spreading the liquid adhesive, in the event of bodily fluid seepage, medical personnel may use a sterile gauze to dry the deployed porous mesh.
[0176] Referring to
[0177] Once the liquid adhesive is applied to over the porous mesh and the therapeutic device, after about 1 minute, medical personnel may check that polymerization is complete by gently dabbing along the length of the porous mesh with a gloved finger, checking for tackiness. When no liquid or tackiness is apparent, the polymerization process is complete. Once the liquid adhesive is polymerized, the therapeutic device may be operated for performing various therapeutic activities including but not limited to draining bodily fluids from the wound, infusing the wound with saline or medications, and/or monitoring the wound using a sensor.
[0178] Referring to
[0179] Referring to
[0180] Referring to
[0181] In one embodiment, the first and second mesh wings 238A, 238B are preferably utilized for positioning the elongated tube 232 over the incision. In one embodiment, the elongated tube 232 and the first and second mesh wings 238A, 238B may be cut to the length of the incision.
[0182] Referring to
[0183] Referring to
[0184] In one embodiment, the elongated tube 232 may have holes and/or slits that are used for draining fluid from a wound/incision or infusing saline or a medication onto the wound/incision. In one embodiment, the elongated tube 232 may be placed on top of a porous mesh and may be adhered to the porous mesh by using a pressure sensitive adhesive.
[0185] In one embodiment, the elongated tube 232 may have two ends, with one end of the elongated tube being attached to a vacuum for draining fluids (e.g., wound exudate) from the wound/incision and one end of tubing being attached to an inlet port for infusing/injecting fluids, saline irrigation, or medication over the wound/incision. The elongated tube is customizable. The length of the elongated tube may be adjusted, and different therapeutic devices may be used with the elongated tube to monitor the incision, etc. The elongated tube may also be flexed (e.g., bent into a curved configuration) for conforming to the shape of the wound/incision.
[0186] Referring to
[0187] In one embodiment, the top surface of the porous mesh 302 is covered by one or more removable top liners. In
[0188] Referring to
[0189] Referring to
[0190] Referring to
[0191] In one embodiment, the liquid adhesive is configured to secure the therapeutic device 326 and the porous mesh over the incision and form a strong seal around the incision. The liquid adhesive may also form a microbial barrier, be waterproof, and/or allow medical personnel to monitor the wound healing process. The liquid adhesive may be any biocompatible adhesive known in the art, for example, a cyanoacrylate-based adhesive, a silicone-based adhesive, etc. as described above.
[0192] Referring to
[0193] In one embodiment, the top surface of the porous mesh 402 is preferably covered by one or more removable top liners. In
[0194] Referring to
[0195] Referring to
[0196] Referring to
[0197] Referring to
[0198] Referring to
[0199] Referring to
[0200] Referring to
[0201] Referring to
[0202] Referring to
[0203] Referring to
[0204] In one embodiment, the therapeutic device 626 may be made of a biocompatible material such as a polymer, silicone, or stainless steel. In one embodiment, the therapeutic device may be transparent.
[0205] In one embodiment, the therapeutic device 626 preferably has a top surface 650, a bottom surface 652, and side walls 654A, 654B that slope outwardly between the top and bottom surfaces 652, 654. In one embodiment, the top and bottom surfaces 650, 652 of the therapeutic device may be parallel to one another. In one embodiment, the therapeutic device 626 may have a low profile and may resemble the shape of a speed bump.
[0206] In one embodiment, the therapeutic device 626 may have a first elongated channel 656A that extends along the length of the therapeutic device. In one embodiment, the therapeutic device 626 preferably includes a first fenestration 658A (e.g., an opening) that is formed in the bottom surface 652 of the therapeutic device, which is in fluid communication with the first elongated channel 656A. In one embodiment, the first fenestration 658A may be positioned over a wound for placing the first elongated channel 656A in fluid communication with the wound. In one embodiment, a vacuum may be coupled with the first elongated channel 656A for draining fluid (e.g., exudate) from the wound. The fluid that is drained from the wound preferably passes through the first fenestration 658A and into the first elongated channel 656A for being removed from the wound. In one embodiment, the therapeutic device may include a first port that is in fluid communication with the first elongated channel 656A for coupling a drain tube with the first elongated channel 656A.
[0207] In one embodiment, the first elongated channel 656A and the first fenestration 658A may be used for infusing a therapeutic solution into the wound.
[0208] In one embodiment, the therapeutic device 626 may have a second elongated channel 656B that extends along the length of the therapeutic device and a second fenestration 658B formed in the bottom surface 652 of the therapeutic device that is in fluid communication with the second elongated channel 656B.
[0209] In one embodiment, the second elongated channel 656B and the second fenestration 658B may be used for draining fluid from a wound and/or for infusing the wound with a therapeutic solution. In one embodiment, the therapeutic device may include a second port that is in fluid communication with the second elongated channel 656B for coupling the second elongated channel with a drainage tube or an infusion tube.
[0210] In one embodiment, the therapeutic device 626 may have a third elongated channel 656C that extends along the length of the therapeutic device and a third fenestration 658C formed in the bottom surface 652 of the therapeutic device that is in fluid communication with the third elongated channel 656C.
[0211] In one embodiment, the third elongated channel 656C and the third fenestration 658C may be used for draining fluid from a wound and/or for infusing a therapeutic solution into the wound. In one embodiment, the therapeutic device may include a third port that is in fluid communication with the third elongated channel 656C for coupling the third elongated channel with a drainage tube or an infusion tube.
[0212] In one embodiment, the therapeutic device 626 may be secured over a top surface of a first layer of a porous dressing so that the first elongated channel 656A of the therapeutic device is positioned over the top surface of the first layer of the porous dressing with the first elongated channel positioned adjacent the wound.
[0213] In one embodiment, a second layer of a porous dressing may be applied over both the first layer of the porous dressing and over the top of the therapeutic device 626 to secure the therapeutic device to the top surface of the first layer of the porous dressing. The second layer of the porous dressing may contact the top surface 650 and the side surfaces 654A, 654B of the therapeutic device 626.
[0214] In one embodiment, a flowable adhesive may be applied over the first layer of the porous dressing, the second layer of the porous dressing and the therapeutic device 626. The flowable adhesive may be cured for forming an air-tight seal around the wound.
[0215] In one embodiment, a tube may be attached to the therapeutic device 626 for draining fluid (e.g., exudate) from the first elongated channel 656A of the therapeutic device. In one embodiment, the tube may be attached to a vacuum for applying negative pressure to the wound for draining fluid from the wound. In one embodiment, the tube may be attached to a therapeutic solution (e.g., saline; medication; an antibiotic solution) for infusing the therapeutic solution into the first elongated channel 656A. The therapeutic solution preferably passes through the first fenestration 658A for infusing the wound with the therapeutic solution.
[0216] In one embodiment, the elongated channel of the therapeutic device 656 desirably has two or more connection ports where fluid may be infused into and/or withdrawn from the wound.
[0217] In one embodiment, the connection ports may be located on the top surface 650 or on one or more of the side surfaces 654A, 654B of the therapeutic device 626. In one embodiment, a connection port may be attached to a vacuum via tubing, which is configured to apply negative pressure to a wound or incision. In one embodiment, a connection port may be attached to an infusing tube for infusing a therapeutic solution (e.g., saline; medication; antibiotic) into a wound or incision.
[0218] In one embodiment, the therapeutic device 626 may be transparent for enabling medical personnel to view the wound or incision during healing. In one embodiment, the flowable adhesive cures to a transparent covering for enabling medical personnel to view the wound or incision during healing. In one embodiment, the flowable adhesive is a silicone material.
[0219] While the foregoing is directed to embodiments of the present invention, other and further embodiments of the invention may be devised without departing from the basic scope thereof, which is only limited by the scope of the claims that follow. For example, the present invention contemplates that any of the features shown in any of the embodiments described herein, or incorporated by reference herein, may be incorporated with any of the features shown in any of the other embodiments described herein, or incorporated by reference herein, and still fall within the scope of the present invention.